Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) fell 17.1% on Thursday . The stock traded as low as C$0.28 and last traded at C$0.32. 684,632 shares changed hands during trading, an increase of 2% from the average session volume of 673,865 shares. The stock had previously closed at C$0.38.
Hemostemix Stock Performance
The company has a market capitalization of C$27.44 million, a price-to-earnings ratio of -15.75 and a beta of 0.20. The company’s fifty day simple moving average is C$0.15 and its two-hundred day simple moving average is C$0.10.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Why is the Ex-Dividend Date Significant to Investors?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Compound Interest and Why It Matters When Investing
- 3 Steel Stocks Soaring After Tariff Announcements
- What is the MACD Indicator and How to Use it in Your Trading
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
